PTeye versus surgeon’s eye for finding and protecting parathyroid glands during total thyroid removal

Clinical Validation of Probe-based Parathyroid Autofluorescence Detection System PTeye vs Surgeons Eyes in Intraoperative Identification and Functional Preservation of Parathyroid Glands During Thyroid Surgery: A Parallel Randomized Controlled Clinical Trial.

Not applicable Interventional Jagiellonian University · NCT06765941

This trial will test whether using the PTeye near-infrared probe during first-time total thyroidectomy in adults helps surgeons find and preserve parathyroid glands better than using the surgeon’s naked eye.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment154 (estimated)
Ages18 Years and up
SexAll
SponsorJagiellonian University Academic / other
Locations1 site (Krakow, Małopolska)
Trial IDNCT06765941 on ClinicalTrials.gov

What this trial studies

This is a single-center, prospective, randomized (1:1) trial comparing use of a probe-based near-infrared autofluorescence device (PTeye) versus standard visual identification by the surgeon during total thyroidectomy. Patients are randomly assigned to PTeye-assisted surgery or to conventional visual identification, and surgeons record the number of parathyroid glands identified and preserved intraoperatively. Key outcomes include the number of glands identified/preserved, postoperative day 1 parathyroid hormone (PTH) levels, and need for calcium and vitamin D replacement in short-term (<6 weeks) and at 6-month follow-up. The planned sample size is 154 patients (77 per arm), accounting for expected dropout, based on a hypothesized increase in average glands identified from 2.5 to 3.5 with PTeye.

Who should consider this trial

Good fit: Adults (age ≥18) with thyroid disease who are scheduled for a first-time total thyroidectomy and who can understand the protocol and attend postoperative follow-up are ideal candidates.

Not a fit: Patients with prior thyroid or parathyroid surgery, planned simultaneous parathyroid surgery, renal failure, pregnancy or lactation, allergy to iodine/contrast, or inability to complete follow-up are excluded and unlikely to benefit from this protocol.

Why it matters

Potential benefit: If successful, using PTeye could reduce accidental parathyroid damage or removal and lower the rates of temporary or permanent postoperative hypoparathyroidism and need for calcium/vitamin D therapy.

How similar studies have performed: Previous smaller studies using near-infrared autofluorescence (including probe-based systems) have generally improved intraoperative detection of parathyroid glands, but evidence that this consistently reduces postoperative hypoparathyroidism is limited and mixed.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* a patient with thyroid disease qualified for first-time total thyroidectomy.

Exclusion Criteria:

* history of thyroid or parathyroid surgery,
* planned simultaneous thyroid and parathyroid surgery,
* renal failure,
* pregnancy,
* lactation,
* allergy to contrast agents and/or iodine,
* inability of the patient to understand the study protocol,
* inability to participate in the planned postoperative follow-up,
* age below 18 years.

Where this trial is running

Krakow, Małopolska

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Thyroid SurgeryParathyroid DysfunctionHypoparathyroidism Post-surgicalthyroid surgerypostoperative hypoparathyroidismnear-infrared autofluorescencePTeyeprobe-based parathyroid detection
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.